Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away . Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

Harris B. H. L.; Walsh J. L.; Neciunaite R.; Manders P.; Cooper A.; De Souza P.

首页> 外文期刊>Clinical and experimental dermatology >Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away . Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

【24h】

Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away . Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

机译：环形戒指，患有Kaposi的患者？ Pazopanib，Pazopanib，它可能会消失一个戒指O'Roses，患者与Kaposi的患者？ Pazopanib，Pazopanib，它可能会消失。 Mediterranean（Classic）Kaposi Sarcoma在多行标准治疗后响应酪氨酸激酶抑制剂Pazopanib

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical and experimental dermatology》 |2018年第2期|共3页
作者
Harris B. H. L.; Walsh J. L.; Neciunaite R.; Manders P.; Cooper A.; De Souza P.;
展开▼
作者单位

Department of Medical OncologyLiverpool HospitalSydney Australia;

St. George's HospitalLondon UK;

Cardiff University School of MedicineCardiff UK;

Department of Medical OncologyLiverpool HospitalSydney Australia;

Department of Medical OncologyLiverpool HospitalSydney Australia;

Department of Medical OncologyLiverpool HospitalSydney Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献

1. Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away . Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy [J] . Harris B. H. L., Walsh J. L., Neciunaite R., Clinical and experimental dermatology . 2018,第2期

机译：环形戒指o'roses，患有卡皮西的患者？ Pazopanib，Pazopanib，它可能会消失一个戒指o'roses，患者与kaposi的患者？ Pazopanib，Pazopanib，它可能会消失。 Mediterranean（Classic）Kaposi Sarcoma在多行标准治疗后响应酪氨酸激酶抑制剂Pazopanib
2. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) [J] . Pautier P., Penel N., Ray-Coquard I., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第1期

机译：吉西他滨的II期与Pazopanib之后的Pazopanib维持联合，作为先进的平滑肌肉瘤患者的二线治疗：一个Unicancer法国肉瘤学习（LMS03学习）
3. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature [J] . Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, Investigational new drugs. . 2018,第2期

机译：Pazopanib，多针对酪氨酸激酶抑制剂的后逆可逆性脑病综合征（PRES），患有软组织肉瘤的患者：病例报告和文献审查
4. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib a multi-targeting tyrosine kinase inhibitor in a patient with soft-tissue sarcoma: case report and review of the literature [O] . Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, -1

机译：多靶点酪氨酸激酶抑制剂帕唑帕尼诱发的软组织肉瘤患者后可逆性脑病综合征（PRES）：病例报告及文献复习
5. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin [O] . Marc R. Matrana, Tharakeswara Bathala, Matthew T. Campbell, 2015

机译：未选择性透明细胞肾细胞癌的未选择患者的结果，用一线Pazopanib疗法治疗，然后进行血管内皮生长因子受体酪氨酸激酶抑制剂或哺乳动物靶蛋白抑制剂的靶标：罪

著录项

相似文献

相关主题

期刊订阅